Amunix Raises $ 117 Million in Series B Funding
Amunix Pharmaceuticals, Inc., a South San Francisco, California-based biopharmaceutical company focused on developing masked and protease-activated immuno-oncology therapies to bring the promise of these potent therapies to patients with solid tumor cancers, has raised 117 million dollars. dollars in Series B funding.
The round was led by Viking Global Investors with participation from a leading syndicate of funds including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital and Polaris Partners.
The company intends to use the funds for the clinical advancement of AMX-818, a protease-activated masked T cell activator (XPAT®) targeting solid tumors expressing HER2, as well as supporting the robust Immunix pipeline of early-stage XPAT® and protease activated masked cytokines (XPACs ™).
Led by Angie You, Ph.D., CEO, Amunix leverages its proprietary XPAT® and the XPAC ™ platforms to advance a pipeline of new drugs that are preferentially activated in the tumor microenvironment and designed to overcome toxicity issues that have hampered other T cell and cytokine therapies. Its proprietary masking technology has been clinically validated to extend the drug’s half-life with limited immunogenicity. The company’s pipeline includes AMX-818, an XPAT® Commitment of T cells targeting a variety of solid tumors expressing HER2, which is currently the subject of studies enabling IND. Along with several other T cell activation programs, Amunix is also applying its proprietary masking technology to its first protease-activated masked cytokine program, IL12-XPAC ™, which is in the discovery phase.